Sanofi Ventures

About Sanofi Ventures

Biotech, Digital Health, Immunology, Neurology, Rare Diseases, Vaccines - evergreen fund

Investment Focus

Location / RegionFrance

Funding StageSeed

Industry Focus

Biotech

Digital Health

Investor Signals Profile

active

Sweet Spot

Early-stage biotech or digital health with pharma M&A potential

immunology

rare diseases

neurology

vaccines

digital health

Bullish Signals

$625M new commitment, $1.4B AUMexternal

11 deals closed in 2025 alreadyexternal

3 exits, $3.25B combined in 2024external

Actively leading rounds vs. traditional VCsexternal

Sanofi pushing derm access — digital health signallinkedin

Derm access crisis — 16M French patients underservedlinkedin

Contrarian Signals

Source is Sanofi, not a VC fundexternal

Strategic CVC — agenda tied to Sanofi pipelineexternal

Acquisition bias may limit founder independenceexternal

LinkedIn content brand-focused, low deal signallinkedin

Derm post PR-driven, no investment intent visiblelinkedin

Founder Do's

Target immunology, neuro, rare disease, vaccines

Open to seed through crossover stage

Show clear M&A attractiveness to big pharma

Prepare strong clinical/preclinical data package

Ophthalmology also on radar

Founder Don'ts

Don't expect passive investor — they co-lead

Don't ignore strategic fit with Sanofi pipeline

Don't pitch without clear exit narrative

Key GPs & Partners

Jason Hafler

Managing Director

lead-round focusedstrategic acquirer lensopportunistic

Unlock Investor Signals

$29/month for full signal access. Cancel anytime.

View Plans Browse all Signal Profiles →

Fund Overview

Fund Size$625M

Saves0

Website

Key People

Jason P. Hafler

Jason HaflerManaging Director